CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study Background <p>CD8 T cells mediate the effects of cancer immunotherapies. CD8 positron emission tomography (PET) imaging with [<sup>89</sup>Zr]Zr-berdoxam-crefmirlimab enables whole body CD8 cell assessment and has been shown to be safe in Phase I evaluation. The correlation between CD8 PET imaging parameters and the quantity of CD8 cells assessed by the gold standard of immunohistochemistry (IHC) is unknown.</p> Methods <p>The… Journal for ImmunoTherapy of Cancer March 29, 2026 Original source
Letter to the Editor: Dynamic Deterioration of Nutritional Status During the Preoperative Period in Gastric Cancer . <br /> Nutrition and Cancer Journal March 28, 2026 Original source
Comment on Impact of Sarcopenia and Osteopenia on Prognosis in Metastatic Biliary Tract Cancer: A Single Center Experience . <br /> Nutrition and Cancer Journal March 27, 2026 Original source
AI-driven smart patient retrieval for precision oncology <p>Nature Reviews Cancer, Published online: 26 March 2026; <a href="https://www.nature.com/articles/s41568-026-00923-1">doi:10.1038/s41568-026-00923-1</a></p>Tumour boards are often constrained by time-intensive data preparation and discussion. In this Comment, Wang and Chaudhari advocate for the use of artificial intelligence (AI)-driven smart patient-retrieval systems to facilitate more informed and individualized clinical decision-making. Nature Reviews Cancer March 26, 2026 Original source
Ramadan as a Strategic Clinical Window for Preventative Oncology and Behavioral Reset . <br /> Nutrition and Cancer Journal March 26, 2026 Original source
Response to correspondence regarding “The value of micro-ultrasound for prostate cancer screening: a retrospective real-world feasibility study” <p>Prostate Cancer and Prostatic Diseases, Published online: 26 March 2026; <a href="https://www.nature.com/articles/s41391-026-01112-9">doi:10.1038/s41391-026-01112-9</a></p>Response to correspondence regarding “The value of micro-ultrasound for prostate cancer screening: a retrospective real-world feasibility study” Prostate Cancer Journal March 26, 2026 Original source
Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production Background <p>Poly-ADP ribose polymerase inhibitors (PARPi) are well-known to treat tumors that are deficient in homologous recombination (HR) DNA repair. However, PARPi can treat breast cancer gene (BRCA) wild-type tumors, the mechanisms behind which are not fully elucidated. We previously reported that tumor-intrinsic programmed death ligand-1 (PD-L1) signals promote HR, and that genetic tumor PD-L1<sup>KO</sup> impairs HR and sensitizes tumors… Journal for ImmunoTherapy of Cancer March 25, 2026 Original source
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer Background <p>Poly(ADP-ribose) polymerase (PARP) inhibition (PARPi) is a precision medicine strategy in advanced prostate cancer, with the greatest benefit seen in a subset of patients with homologous recombination repair (HRR) gene alterations. Combination approaches may expand activity beyond HRR-altered disease. We conducted a phase 2 study of the PARP inhibitor olaparib in combination with the anti-PD-L1 antibody durvalumab in an… Journal for ImmunoTherapy of Cancer March 25, 2026 Original source
Targeting SPP1+TAMs associated with liver metastasis reverses immunosuppression and synergizes with immunotherapy in colorectal cancer Background <p>Tumor-associated macrophages (TAMs) are critically involved in colorectal cancer (CRC) progression, yet their spatial and metabolic heterogeneity across primary and metastatic microenvironments remains poorly defined, limiting therapeutic development.</p> Methods <p>Integrated single-cell RNA sequencing was performed on 998,204 cells from a multicenter cohort encompassing primary CRC, adjacent normal tissue, liver and lymph node metastases, and peripheral blood. Computational analyses included… Journal for ImmunoTherapy of Cancer March 25, 2026 Original source
Vaccinia virus armed with IL-21 can cure murine colorectal cancer liver metastases via intravenous administration Background <p>Liver metastases of colorectal cancer are one of the leading causes of mortality in patients with colorectal cancer. Oncolytic virus immunotherapy has demonstrated significant potential in tumor treatment; however, most oncolytic viruses are currently administered via intratumoral injection, limiting their broader clinical application.</p> Methods <p>In this study, we used an oncolytic vaccinia virus VVLTK-STCN1L-mIL21 expressing interleukin-21 to treat a… Journal for ImmunoTherapy of Cancer March 25, 2026 Original source
Functional m<sup>6</sup>A site detection by FOCAS <p>Nature Reviews Cancer, Published online: 25 March 2026; <a href="https://www.nature.com/articles/s41568-026-00926-y">doi:10.1038/s41568-026-00926-y</a></p>In this Tools of the Trade article, Yifan Zhang describes the development and use of FOCAS, a platform for site-specific, transcriptome-wide mapping of functional m6A RNA modifications, revealing widespread intra-transcript functional diversity and uncovering epitranscriptomic and epigenomic interactions that shape cancer cell fitness. Nature Reviews Cancer March 25, 2026 Original source
Changing the Trajectory of Brain Cancer with a Stronger Immune Defense <p>One by one, our immune cells march to the frontlines when it gets a whiff of an invader. They are ready to fight and protect our systems from what is about to attack. But what if we can recruit these specialized soldiers for glioblastoma — a malignant brain cancer that struggles to have enough immune ... <a class="read-more" href="https://blog.dana-farber.org/insight/2026/03/boosting-immune-response-brain-cancer/" title="Changing… Dana-Farber Cancer Institute March 25, 2026 Original source
IL-12-secreting CAR-T cells reprogram the tumor microenvironment and improve efficacy against heterogeneous models of glioblastoma Background <p>Glioblastoma (GBM) remains uniformly lethal due to pronounced intratumoral heterogeneity and a highly immunosuppressive microenvironment that limits the efficacy of targeted therapies.</p> Methods <p>We engineered chimeric antigen receptor (CAR) T cells targeting Epidermal Growth Factor Receptor variant III (EGFRvIII) and armored them with a single-chain interleukin-12 (scIL12) payload. These cells were tested in syngeneic, orthotopic GBM mouse models exhibiting… Journal for ImmunoTherapy of Cancer March 24, 2026 Original source
Targeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma Background <p>Immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell (CAR-T) immunotherapies have revolutionized the treatment of hepatocellular carcinoma (HCC). However, the frequent emergence of treatment resistance significantly limits the clinical efficacy of HCC immunotherapy. The molecular mechanisms underlying therapy resistance remain poorly understood.</p> Methods <p>To delineate the immune impact of nuclear factor erythroid 2-related factor 2 (Nrf2) inhibition, we… Journal for ImmunoTherapy of Cancer March 24, 2026 Original source
Mitochondrial dysfunction in urologic disease <p>Prostate Cancer and Prostatic Diseases, Published online: 24 March 2026; <a href="https://www.nature.com/articles/s41391-026-01097-5">doi:10.1038/s41391-026-01097-5</a></p>Mitochondrial dysfunction in urologic disease Prostate Cancer Journal March 24, 2026 Original source
For Preschooler with ALL, Sisterly Bond Is a Source of Strength <p>The first time Ashley Bernath dropped her then-three-year-old daughter, Charlie, off at preschool, there was no hug, no tears, no long goodbye — just a quick “see you later” and a full-steam-ahead dash for the classroom. Charlie’s excitement that morning in September 2025 was understandable. She had spent the previous 15 months in active cancer ... <a class="read-more" href="https://blog.dana-farber.org/insight/2026/03/childhood-leukemia-sister-bond/" title="For… Dana-Farber Cancer Institute March 24, 2026 Original source
Striking the right balance with type I interferon signalling in cancer <p>Nature Reviews Cancer, Published online: 23 March 2026; <a href="https://www.nature.com/articles/s41568-026-00915-1">doi:10.1038/s41568-026-00915-1</a></p>Type I interferons (IFNs) critically influence cancer development, progression and therapeutic response. In this Review, Parker, Haynes and colleagues explore the complexity of IFN signalling, with a particular focus on tumour-intrinsic mechanisms, and outline strategies for reprogramming IFN activity in tumours to enhance anticancer immunity and improve patient outcomes. Nature Reviews Cancer March 23, 2026 Original source
Lifestyle matters: physical activity and prostate cancer progression <p>Prostate Cancer and Prostatic Diseases, Published online: 23 March 2026; <a href="https://www.nature.com/articles/s41391-026-01105-8">doi:10.1038/s41391-026-01105-8</a></p>Lifestyle matters: physical activity and prostate cancer progression Prostate Cancer Journal March 23, 2026 Original source
Limited expression of B-cell maturation antigen in acute myeloid leukemia <p>B-cell maturation antigen (BCMA) was recently identified as a target of T-cell-directed therapy for acute myeloid leukemia (AML), based on the study reporting high BCMA abundance in AML cells using the flow cytometry anti-BCMA antibody clone 19F2 (BCMA-19F2). However, our independent investigation demonstrated limited BCMA levels in both AML patient samples and AML cell lines through the analysis of established… Journal for ImmunoTherapy of Cancer March 23, 2026 Original source
Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study Background <p>The discovery and therapeutic application of immune checkpoint inhibitors (ICIs) have significantly improved clinical outcomes in cancer treatment. However, the response rate is still low in gastrointestinal (GI) cancers. The gut microbiome’s impact on immune modulation is a promising area for overcoming resistance to immunotherapy.</p> Methods <p>This study (NCT04130763) is an open-label, single-arm, single-center, phase I study assessing the… Journal for ImmunoTherapy of Cancer March 23, 2026 Original source